Ember LifeSciences boosts Series A to $27M with new strategic backers
What's the deal? Ember LifeSciences, a cold chain logistics startup spun out of the company behind the popular temperature-control mug, has secured strategic investments from AmgenDealroom has a profile for this one. Try Dealroom → Ventures and TDF VenturesDealroom has a profile for this one. Try Dealroom →. The new capital brings its total Series A to $27 million, building on a round previously led by Sea Court CapitalDealroom has a profile for this one. Try Dealroom →.
Financial terms of the individual investments were not disclosed. The Los Angeles-based company announced the funding alongside the full commercial launch of its Ember Cube 2, a reusable, modular shipping container with real-time monitoring and cloud-based tracking.
Why now? The pharmaceutical cold chain loses billions of dollars annually to temperature excursions — and the problem is getting worse. More medicines and vaccines require temperature-controlled distribution, putting pressure on the industry to modernise its logistics infrastructure.
Ember's timing aligns with that urgency. Its flagship Ember Cube was named a 2024 TIME Invention of the Year and a 2024 Fast Company World Changing Idea. The Ember Cube 2 recently won a "Best of the Best" Red Dot Award for product design.
"Investments from Amgen and TDF Ventures provide us with the deep industry insights needed to scale our logistics platform rapidly," said Clay Alexander, founder and chief executive officer. "Their investments mark a turning point as we expand our global footprint."
What could go wrong? Ember faces well-funded incumbents in pharmaceutical logistics, and its reusable model requires customers to overhaul entrenched single-use shipping habits. Scaling hardware-dependent supply chain solutions globally is capital-intensive and operationally complex — $27M may not stretch far.
The signal: Amgen Ventures' participation turns this from a pure logistics bet into a pharma-validated one — corporate venture arms of major biotechs rarely back supply chain startups unless the pain point is acute and the solution has cleared internal due diligence. Ember's breakout-stage classification on Dealroom, combined with a customer roster that already includes CVS HealthDealroom has a profile for this one. Try Dealroom → and Cardinal HealthDealroom has a profile for this one. Try Dealroom →, suggests it is past the pilot phase and entering a scaling window where strategic capital matters more than volume of funding.
Read more: prnewswire.com
